The present findings support this hypothesis, as the relative levels of carnitine, propionylcarnitine, and isobutyryl-L-carnitine were significantly increased in TP53-wildtype GBM but were not significantly different from control patients or patients with TP53-mutant GBM (Fig. 6). The gene discussed is TP53; the disease is glioblastoma.